| 37.83 0.01 (0.03%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 48.78 | 1-year : | 52.55 |
| Resists | First : | 41.77 | Second : | 45 |
| Pivot price | 42.03 |
|||
| Supports | First : | 36.54 | Second : | 30.4 |
| MAs | MA(5) : | 39.29 |
MA(20) : | 42.45 |
| MA(100) : | 40.25 |
MA(250) : | 36.85  |
|
| MACD | MACD : | -0.8 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 10.4 |
D(3) : | 10.3 |
| RSI | RSI(14): 34.3 |
|||
| 52-week | High : | 55 | Low : | 26.85 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ OMCL ] has closed above bottom band by 4.3%. Bollinger Bands are 10.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 38.98 - 39.23 | 39.23 - 39.47 |
| Low: | 36.85 - 37.17 | 37.17 - 37.47 |
| Close: | 37.33 - 37.84 | 37.84 - 38.3 |
Omnicell, Inc., founded in 1992 and headquartered in Mountain View, California (initially operating as Omnicell Technologies, Inc. until its name change in 2001), delivers advanced medication management technologies and patient adherence solutions. The company serves healthcare systems and pharmacies both domestically within the United States and globally. Its extensive portfolio of offerings includes: Clinical Workflow Automation: Omnicell provides automated solutions designed to streamline clinician tasks in patient care environments. This encompasses the XT Series automated dispensing units for medications and supplies across nursing units, clinical areas, and surgical suites. They also offer interface software to ensure smooth integration between their products and a healthcare facility's existing information systems, alongside robotic systems for automated storage and retrieval of packaged medications. Central Pharmacy Optimization: For the central pharmacy, Omnicell offers sophisticated automation, including automated storage and retrieval platforms like the XR2 Automated Central Pharmacy System. This segment also features robotic systems and workflow management tools for IV compounding, comprehensive inventory management software, and systems for controlled substance oversight. Single-Dose Packaging for Adherence: The company develops automated technologies for filling and labeling patient-specific, single-dose medication blister packaging according to prescriptions. This includes both fully and semi-automated equipment for institutional pharmacies to ensure precise packaging, along with blister card packaging and supplies aimed at improving medication adherence, particularly in non-acute care settings. Digital Patient Engagement: Omnicell further provides EnlivenHealth Patient Engagement, a web-based platform offering various tools to interact with patients.
Tue, 09 Jun 2026
Omnicell: Why I’m Long Into Q2 Earnings Despite The Bookings Wobble (NASDAQ:OMCL) - Seeking Alpha
Fri, 05 Jun 2026
Omnicell (OMCL) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Thu, 04 Jun 2026
Omnicell (OMCL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Wed, 03 Jun 2026
Omnicell (OMCL) director Mark Parrish receives 4,845-share board compensation grant - Stock Titan
Wed, 03 Jun 2026
Omnicell (OMCL) director awarded 4,603 restricted shares as board compensation - Stock Titan
Wed, 03 Jun 2026
Omnicell (OMCL) director receives 4,785-share stock grant - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 45 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 105.6 (%) |
| Shares Short | 2,680 (K) |
| Shares Short P.Month | 2,520 (K) |
| EPS | 0.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 27.36 |
| Profit Margin | 1.6 % |
| Operating Margin | 5.4 % |
| Return on Assets (ttm) | 1.2 % |
| Return on Equity (ttm) | 1.6 % |
| Qtrly Rev. Growth | 14.8 % |
| Gross Profit (p.s.) | 11.81 |
| Sales Per Share | 27.04 |
| EBITDA (p.s.) | 1.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 156 (M) |
| Levered Free Cash Flow | 113 (M) |
| PE Ratio | 85.97 |
| PEG Ratio | 15.3 |
| Price to Book value | 1.38 |
| Price to Sales | 1.39 |
| Price to Cash Flow | 11.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|